http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-602451-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
filingDate 2011-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b36a712b5cc604743111b05948fb23f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24b15ac09fe42a689adf022f7c01c408
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c725269abc2b4a95882af617e9e5452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8448732ce280b597a98e15053d5272e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b29fbd4963dc6e08a3fafc809bcdc939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b26dc23f2d272f8797b0e3750fa13a7f
publicationDate 2014-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-602451-A
titleOfInvention Agomelatine hydrobromide hydrate and preparation thereof
abstract Disclosed herein is an agomelatine hydrobromide hydrate of formula I and a method for its production wherein agomelatine is dissolved in organic solvent, preferablly ethyl acetate, before being reacted with aqueous HBr solution to produce said hydrobromide hydrate salt. The salt is useful in the treatment melatoninergic system disorders, sleep disorders, stress, anxiety, seasonal affective disorder, major depression, cardiovascular diseases, digestive system diseases, insomnia and fatigue caused by jet lag, schizophrenia, phobia or depression disorders.
priorityDate 2010-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538408
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID82148
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480088
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449212221
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22326455

Total number of triples: 38.